Privia Health Group, Inc. - PRVA STOCK NEWS

Privia Health Group, Inc. (Nasdaq: PRVA) has received the 2022 MAP Award for High Performance in Revenue Cycle from the Healthcare Financial Management Association, marking the seventh consecutive year of recognition. This award acknowledges Privia's excellence in revenue cycle management and its adherence to industry standards, reflecting strong patient satisfaction and operational effectiveness. The award was presented on June 26 during the HFMA Annual Conference in Denver, CO. Privia’s commitment to operational excellence is underscored by its focus on financial health and meaningful value for provider partners.

ARLINGTON, Va., June 1, 2022 (GLOBE NEWSWIRE) -- Privia Health Group (Nasdaq: PRVA) announced its management's participation in upcoming investor conferences. The events include a fireside chat on Tuesday, June 7 at 11:00 am ET during the William Blair Growth Stock Conference, and on Thursday, June 9 at 9:30 am ET at the Jefferies Healthcare Conference. Live webcasts and replays of these sessions will be available online. Privia Health is a technology-driven physician enablement company focused on optimizing practices and improving patient experiences.

Privia Health Group, Inc. (NASDAQ: PRVA) reported a strong Q1 2022 with total revenue reaching $313.8 million, up 46.9% from the previous year. However, the company faced an operating loss of $11.5 million and a net loss of $17.5 million, significantly worse than the prior year's net income of $5.4 million. The adjusted net income was $14.8 million, reflecting a 61.3% increase year-over-year. Key metrics like Practice Collections surged 63.3%, and the company updated its 2022 financial guidance, indicating robust growth prospects.

Privia Health Group, Inc. (Nasdaq: PRVA) will release its financial results for Q1 2022 on May 12, 2022, before market opening. The press release will be available at 7:00 am ET on their Investor Relations website. Management will host a conference call at 8:30 am ET to discuss the results and future outlook, accessible via webcast or by dialing 855-940-5315. An archive of the webcast will be available shortly after the call concludes. Privia Health focuses on optimizing physician practices and improving patient experiences through technology-driven solutions.

Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Nancy Cocozza to its Board of Directors, expanding the board to ten members. Cocozza, a former Medicare business leader at Aetna, will also join the Audit Committee. CEO Shawn Morris highlighted her extensive healthcare industry expertise as a key asset for the company's growth in value-based care. Cocozza expressed enthusiasm for contributing to the company’s success. With over 30 years of experience, she brings valuable insights to tackle healthcare challenges.

Privia Health Group, Inc. (Nasdaq: PRVA) reported strong financial results for FY 2021, exceeding guidance with total revenue of $966.2 million, a 18.3% increase year-over-year. The fourth quarter revenue rose 28.8% to $275.3 million. Despite an operating loss of $217.4 million for FY 2021, non-GAAP adjusted net income was $41.6 million. The company anticipates continued growth with FY 2022 guidance projecting practice collections to reach between $2.05B and $2.2B, reflecting a 26.1%-35.3% increase. Additionally, new market entries and ACO expansions are expected to enhance profitability.

Amalgam Rx and Privia Health have announced a collaboration to enhance provider workflows through EHR-integrated services. This partnership aims to simplify value-based care, clinical trial recruitment, and medication safety. Notable offerings from Amalgam include Payer Configured Value-Based Care Rules, Clinical Trial Recruitment tools, and Medication Safety algorithms. This collaboration aligns with Privia's strategy to reduce costs and improve patient outcomes as it moves towards value-based care.

ARLINGTON, Va., Feb. 15, 2022 — Privia Health Group (Nasdaq: PRVA) will participate in a virtual fireside chat during the SVB Leerink 11^th Annual Global Healthcare Conference on February 16, 2022, at 4:20 pm ET. The event will be accessible through a webcast along with a replay and accompanying slide presentation available on their website.

Privia Health is a technology-driven company focused on enhancing physician practices, patient experiences, and healthcare outcomes.

On February 14, 2022, Javara announced a clinical trial for an investigational vaccine, mRNA-1345, aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older. This trial, conducted in partnership with Privia Health and Moderna (Nasdaq: MRNA), will enroll approximately 34,000 participants across Fayetteville, Annapolis, and Fort Worth. RSV causes significant health issues, with over 177,000 hospitalizations yearly among older adults in the U.S. The trial aims to evaluate the vaccine's safety and efficacy, addressing the urgent need for preventive measures against RSV.